Search
01/07/2022
Beyond plaque psoriasis - pathogenesis and treatment of other psoriasis phenotypes
Iznardo, H, Puig, L. Beyond plaque psoriasis - pathogenesis and treatment of other psoriasis phenotypes. CURRENT OPINION IN RHEUMATOLOGY. 2022; 34(4)DOI:10.1097/BOR.0000000000000882. PMID:35699337. IF:5.100(Q2/3D).
01/07/2022
Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis
Serra-Baldrich, E, Santamaria-Babi, LF, Silvestre, JF. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis. Actas Dermo-Sifiliograficas. 2022; 113(7)DOI:10.1016/j.ad.2021.12.014. PMID:35842249. IF:(Q/D).
01/06/2022
Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials
Chabra, S, Gill, BJ, Gallo, G, Zhu, DT, Pitou, C, Payne, CD, Accioly, A, Puig, L. Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials. ADVANCES IN THERAPY. 2022; 39(6)DOI:10.1007/s12325-022-02126-0. PMID:35449322. IF:3.800(Q2/4D).
01/06/2022
A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence
Medina-Catalan, D, Riera, P, Pages-Puigdemont, N, Masip, M, Lopez-Ferrer, A, Vilarrasa, E, Puig, L. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. International Journal of Clinical Pharmacy. 2022; 44(3)DOI:10.1007/s11096-022-01400-z. PMID:35380392. IF:2.400(Q3/8D).